Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALDHlow-TPDC
- Development stage
- Preclinical
- Lead developer
- University of Michigan
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
ALDHlow-TPDC is an experimental cancer vaccine consisting of dendritic cells (DCs) pulsed with the lysate of tumor cells characterized by low aldehyde dehydrogenase (ALDH) activity. In the context of cancer stem cell (CSC) research, ALDH is often used as a marker to identify and isolate CSCs (ALDHhigh). ALDHlow cells represent the non-stem cell population of the tumor. This vaccine was developed as a control or comparator to CSC-based vaccines (such as CSC-TPDC) to evaluate the specific immunogenicity and therapeutic efficacy of targeting cancer stem cells versus the bulk tumor population. Research conducted at the University of Michigan using murine melanoma (D5) and squamous cell cancer (SCC7) models demonstrated that while ALDHlow-TPDC can induce some anti-tumor immunity, it is significantly less effective than vaccines derived from ALDHhigh CSCs in inhibiting tumor growth and prolonging survival.
- Other names
- ALDHlow tumor-pulsed dendritic cellsALDHlow D5 lysate-pulsed dendritic cells
02
Targets
Tumor-associated antigen–derived peptides presented on Human Leukocyte Antigen class ICD28 (Cluster of Differentiation 28)TAA-HLA-II (Tumor-associated antigen–derived peptides presented on Human Leukocyte Antigen class II)
Beyond the preview
Go deeper on ALDHlow-TPDC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALDHlow-TPDC.